Pure Global AI
NCT06275360Recruiting

Repositioning Immunotherapy in VetArans With Lung Cancer

Repositioning Immunotherapy in Veterans With Lung Cancer
VA Office of Research and DevelopmentPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non-Small Cell Lung Cancer
Drug/Device/Intervention
Nivolumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
VA Office of Research and Development
Location
West Los Angeles,West Haven,Ann Arbor,Omaha,Durham,Cleveland,Richmond, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Mar 01, 2024
End date
Mar 31, 2030
Enrollment
25 participants
Primary outcome

Progression-free survival,Treatment Tolerance

Summary

This study is a multicenter Phase II single arm trial to assess the safety and efficacy of
 chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage
 III NSCLC.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06275360
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06275360 through Pure Global AI's free database. This Phase 2 trial is sponsored by VA Office of Research and Development and is currently Recruiting. The study focuses on Non-Small Cell Lung Cancer. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.